Back to Trials
NCT06566716Recruiting

A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women with an Ovarian Mass

Cleo Diagnostics Ltd

Start Date

9/6/2024

Completion Date

8/1/2026

Summary

Ovarian cancer is a serious health risk with the highest death rate among gynecological cancers. Unfortunately, it's only possible to definitively diagnose ovarian cancer after surgery, as there are no reliable tests to determine if an ovarian abnormality is cancerous or benign before surgery. Cleo Diagnostics have developed a new test that uses five biomarkers in the blood to better differentiate between benign and malignant ovarian conditions. In initial studies, this test outperformed the current standard test, CA125, in identifying cancer. This study aims to evaluate the effectiveness of the Cleo Diagnostics (CleoDX) Ovarian Adnexal Mass Score Test System. This test measures five analytes in the blood and provides a score indicating the likelihood of cancer in patients with an adnexal mass requiring surgery. The test is designed to assist doctors in making better-informed decisions about surgery and patient care by providing a more accurate pre-surgical assessment of cancer risk. By doing so, it aims to improve patient outcomes and ensure that those with malignant conditions receive the appropriate specialist care.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * female patients =\> 18 years of age at the time of consent * Can provide written informed consent * Have an ovarian cyst or adnexal mass (simple, complex, or solid ovarian/pelvic mass) identified through imaging examination (e.g. transvaginal ultrasound - TVU) that requires surgery, but have not yet undergone this surgery Exclusion Criteria: * Any prior confirmed diagnosis of, or treatment for, ovarian cancer * Any prior surgery resulting in removal of both ovaries * Prior history of gynecological malignancy (within last 2 years) * Prior history of melanoma (within last 2 years) * Prior treatment (within 12 months of sample collection) with chemotherapy, radiotherapy or immunotherapy * Immune-compromised. Definition: those whose weakened immune system may render them more susceptible to infection, illness, or complications. These may include patients with immune-suppressive conditions (e.g. HIV/AIDS), patients undergoing immuno-, chemo- or radio-therapy (within the last 12 months) for any reason, receiving immune suppressive therapies (e.g. transplant recipients, individuals with known autoimmune disease), or with a primary immunodeficiency disorder (e.g. Lupus). * Pregnant currently or within the last 3 months based on participant self-report

Interventions

DIAGNOSTIC_TEST

CleoDX ovarian cancer test

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Ovarian Neoplasms

Locations

New Horizons Clinical Trials

Chandler, Arizona 85224

United States

Emerald Coast Clinical Research

Panama City, Florida 32405

United States

Women's Cancer Center of Nevada

Las Vegas, Nevada 89106

United States

The Jackson Clinic

Jackson, Tennessee 38305

United States

Next Innovative Clinical Research

Houston, Texas 77008

United States

Prime Clinical Research - Lewisville

Lewisville, Texas 75067

United States

Vast Clinical Research-Holy Cross

Mesquite, Texas 75149

United States

Virginia Women's Health Associates

Annandale, Virginia 22003

United States